<DOC>
	<DOCNO>NCT02688686</DOCNO>
	<brief_summary>The purpose Phase I/II study evaluate safety efficacy dendritic cell ( DC ) vaccine combine cytokine-induced killer ( CIK ) cell patient Advanced Non-Small-Cell Lung Cancer bone metastasis . Experimental DC transfected Ad5 vector cod mRNAs include suppressor cytokine signaling ( SOCS ) 1 , MUC1 Survivin , use DC-based immunotherapy . Based result previously preclinical study DC vaccine combine CIK cell , investigator plan perform clinical trial .</brief_summary>
	<brief_title>Safety Efficacy DC-CIK Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<criteria>Histopathologically confirm diagnosis nonsmall cell lung cancer Age &gt; 18 year time consent Received standardize treatment NonSmallCell Lung Cancer bone metastases KPS ( Karnofsky performance scale ) &gt; 60 Patient 's write informed consent No severe viral bacterial infection Predicted survival &gt; 3 month Clinically relevant disease infection ( HBV , HCV , HIV ) Females pregnant nursing Immunosuppressant treatment Currently participate another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>